Hemodiafiltration is associated with reduced inflammation, oxidative stress and improved endothelial risk profile compared to high-flux hemodialysis in children

Ayşe Ağbaş, Nur Canpolat, Salim Çalışkan, Alev Yılmaz, Hakan Ekmekçi, Mark Mayes, Helen Aitkenhead, Franz Schaefer, Lale Sever, Rukshana Shroff, Ayşe Ağbaş, Nur Canpolat, Salim Çalışkan, Alev Yılmaz, Hakan Ekmekçi, Mark Mayes, Helen Aitkenhead, Franz Schaefer, Lale Sever, Rukshana Shroff

Abstract

Randomized trials in adults have shown reduced all-cause and cardiovascular mortality on hemodiafiltration (HDF) compared to high-flux hemodialysis (HD), but the mechanisms leading to improved outcomes are not clear. We studied biomarkers of inflammation, oxidative stress, anti-oxidant capacity and endothelial dysfunction in 22 children (13 female, age 8-15 years). All children received HD for at least 3 months, and were then switched to HDF, keeping all dialysis related parameters and dialysis time constant. All the biomarkers of inflammation (ß2-microglobulin, IL-6, IL-10, high sensitive C-reactive protein [hsCRP]), oxidative stress (nitrotyrosine, advanced glycation end-products [AGEs], oxidized low density lipoprotein [ox-LDL] and anti-oxidant capacity) and endothelial dysfunction (asymmetric dimethyl arginine [ADMA], symmetric dimethyl arginine [SDMA]), were comparable between incident and prevalent patients on HD, suggesting that even a short dialysis vintage of 3 months on HD increases inflammation and endothelial stress. After 3 months of HDF therapy there was a significant reduction in ß2-microglobulin (p<0.001), hCRP, ADMA, SDMA, AGEs, ox-LDL (p<0.01 for all) and an increase in total antioxidant capacity (p<0.001) compared to HD. All children were maintained on the same dialyser, dialysis water quality, dialysis time and blood flow speeds suggesting that improved clearances on HDF led to an improved biomarker profile. Even in children with residual renal function there was a significant reduction in ß2 microglobulin, hsCRP, SDMA, ox-LDL and AGEs on HDF compared to HD. Children with a lower blood flow had higher inflammatory status (higher IL-6/IL-10 ratio; p = 0.04, r = -0.43). Children who achieved a higher convective volume (≥median 12.8L/m2) had lower ox-LDL (p = 0.02). In conclusion, we have shown that a significant improvement in inflammation, antioxidant capacity and endothelial risk profile is achieved even within a short time (3 months) on HDF compared to HD treatment.

Trial registration: ClinicalTrials.gov: NCT02063776.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flow chart of the study.
Fig 1. Flow chart of the study.
22 eligible chronic HD patients were recruited from two centers. Patients were treated with at least 3 months on high-flux HD and then switched to post-dilution online-HDF for 3 months. Dialysis prescription (time, blood flow rate, dialysate flow rate, dialyser type and size) and vascular access type were kept constant during each period.
Fig 2. Comparison of biomarkers in children…
Fig 2. Comparison of biomarkers in children on high-flux HD and HDF.
(A) Markers of oxidative stress (ox-LDL, AGEs) were significantly reduced in addition to improvement in total antioxidant capacity, however nitrosative stress (nitrotyrosine) was not changed on HDF compared to HD. (B) Markers of inflammation (ß2M, hsCRP) except IL-6 were reduced significantly while anti-inflammatory marker IL-10 was not changed on HDF compared to HD. (C) Markers of endothelial dysfunction (ADMA, SDMA) were reduced significantly on HDF compared to HD.
Fig 3
Fig 3
Percent increase in TAC and percent decrease in SDMA from HD to HDF was more pronounced in patients with higher blood flow rate (A,B). Higher blood flow rate was also associated with lower IL-6 to IL-10 ratio on HDF (C). Percent change = [(HDF-HD)/HD]*100.
Fig 4. Comparison of biomarkers in children…
Fig 4. Comparison of biomarkers in children with and without residual renal function (RRF) on high-flux HD and HDF.
Markers of oxidative stress (A), inflammation (B) and endothelial dysfunction (C) were significantly decreased in addition to a significant increase in anti-oxidant capacity on HDF compared to HD. This improvement was observed not only in patients without RRF but also in patients with RRF.
Fig 5. Demonstrating the molecular weights of…
Fig 5. Demonstrating the molecular weights of the studied markers and comparison with albumin.
AGEs are not shown in the figure because they are composed of several molecules, which are mostly middle molecules.

References

    1. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol. 2012;23(4):578–85. doi: ; PubMed Central PMCID: PMC3312513.
    1. Health NIo. US Renal Data System, USRDS 2011 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases. 2011.
    1. Civilibal M, Caliskan S, Oflaz H, Sever L, Candan C, Canpolat N, et al. Traditional and "new" cardiovascular risk markers and factors in pediatric dialysis patients. Pediatr Nephrol. 2007;22(7):1021–9. doi: .
    1. Dai L, Golembiewska E, Lindholm B, Stenvinkel P. End-stage renal disease, inflammation and cardiovascular outcomes. Contrib Nephrol. 2017;191:32–43. doi: .
    1. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013;24(2):179–89. doi: .
    1. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J, et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008;19(5):863–70. doi: .
    1. Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-George F, et al. Does uremia cause vascular dysfunction? Kidney Blood Press Res. 2011;34(4):284–90. Epub 2011/06/22. doi: .
    1. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006;17(2):546–55. doi: .
    1. Leurs P, Lindholm B, Stenvinkel P. Effects of hemodiafiltration on uremic inflammation. Blood Purif. 2013;35 Suppl 1:11–7. doi: .
    1. Tattersall JE, Ward RA, group E. Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant. 2013;28(3):542–50. doi: .
    1. Peters SA, Bots ML, Canaud B, Davenport A, Grooteman MP, Kircelli F, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant. 2016;31(6):978–84. doi: .
    1. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013;24(3):487–97. doi: ; PubMed Central PMCID: PMC3582206.
    1. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013;28(1):192–202. doi: .
    1. Bellien J, Freguin-Bouilland C, Joannides R, Hanoy M, Remy-Jouet I, Monteil C, et al. High-efficiency on-line haemodiafiltration improves conduit artery endothelial function compared with high-flux haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant. 2014;29(2):414–22. doi: .
    1. Nube MJ. Why is high volume online post-dilution hemodiafiltration associated with improved survival? In: Nube MJ GM, Blankestijn P, editor. Hemodiafiltration, Theory, Technology and Clinical practice. 1st ed: Springer; 2016. p. 239–54.
    1. Fischbach M, Attal Y, Geisert J. Hemodiafiltration versus hemodialysis in children. Int J Pediatr Nephrol. 1984;5(3):151–4. .
    1. Fischbach M, Terzic J, Menouer S, Dheu C, Seuge L, Zalosczic A. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol Dial Transplant. 2010;25(3):867–73. doi: .
    1. Fadel FI, Makar SH, Zekri H, Ahmed DH, Aon AH. The effect of on-line hemodiafiltration on improving the cardiovascular function parameters in children on regular dialysis. Saudi J Kidney Dis Transpl. 2015;26(1):39–46. .
    1. Morad AA, Bazaraa HM, Abdel Aziz RE, Abdel Halim DA, Shoman MG, Saleh ME. Role of online hemodiafiltration in improvement of inflammatory status in pediatric patients with end-stage renal disease. Iran J Kidney Dis. 2014;8(6):481–5. .
    1. Ariza F, Merino A, Carracedo J, Alvarez de Lara MA, Crespo R, Ramirez R, et al. Post-dilution high convective transport improves microinflammation and endothelial dysfunction independently of the technique. Blood Purif. 2013;35(4):270–8. doi: .
    1. Carracedo J, Merino A, Nogueras S, Carretero D, Berdud I, Ramirez R, et al. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: A prospective, crossover study. J Am Soc Nephrol. 2006;17(8):2315–21. doi: .
    1. den Hoedt CH, Bots ML, Grooteman MP, van der Weerd NC, Mazairac AH, Penne EL, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int. 2014;86(2):423–32. doi: .
    1. Santoro A, Mancini E. Is hemodiafiltration the technical solution to chronic inflammation affecting hemodialysis patients? Kidney Int. 2014;86(2):235–7. doi: .
    1. Maduell F, Arias-Guillen M, Fontsere N, Ojeda R, Rico N, Vera M, et al. Elimination of large uremic toxins by a dialyzer specifically designed for high-volume convective therapies. Blood Purif. 2014;37(2):125–30. doi: .
    1. Basile C, Davenport A, Blankestijn PJ. Why choose high volume online post-dilution hemodiafiltration? Journal of nephrology. 2017;30(2):181–6. doi: .
    1. Canaud B, Koehler K, Bowry S, Stuard S. What is the optimal target convective volume in on-line hemodiafiltration therapy? Contrib Nephrol. 2017;189:9–16. doi: .
    1. Movilli E, Camerini C, Gaggia P, Zubani R, Feller P, Salviani C, et al. Total convection affects serum beta2 microglobulin and C-reactive protein but not erythropoietin requirement following post-dilutional hemodiafiltration. Am J Nephrol. 2015;41(6):494–501. doi: .
    1. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17(12):3458–71. doi: .
    1. Vilar E, Boltiador C, Wong J, Viljoen A, Machado A, Uthayakumar A, et al. Plasma levels of middle molecules to estimate residual kidney function in haemodialysis without urine collection. PLoS One. 2015;10(12):e0143813 doi: ; PubMed Central PMCID: PMC4668015.
    1. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38(1):85–90. doi: .
    1. Penne EL, van der Weerd NC, Blankestijn PJ, van den Dorpel MA, Grooteman MP, Nube MJ, et al. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol. 2010;5(1):80–6. doi: ; PubMed Central PMCID: PMC2801642.
    1. Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int. 2006;69(8):1431–7. doi: .
    1. Panichi V, Manca-Rizza G, Paoletti S, Taccola D, Consani C, Filippi C, et al. Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs online haemodiafiltration: a cross-over randomized multicentre trial. Nephrol Dial Transplant. 2006;21(3):756–62. doi: .
    1. Filiopoulos V, Hadjiyannakos D, Metaxaki P, Sideris V, Takouli L, Anogiati A, et al. Inflammation and oxidative stress in patients on hemodiafiltration. Am J Nephrol. 2008;28(6):949–57. doi: .
    1. Vaslaki LR, Berta K, Major L, Weber V, Weber C, Wojke R, et al. On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study. Artif Organs. 2005;29(5):406–12. doi: .
    1. Calo LA, Naso A, Davis PA, Pagnin E, Corradini R, Tommasi A, et al. Hemodiafiltration with online regeneration of ultrafiltrate: effect on heme-oxygenase-1 and inducible subunit of nitric oxide synthase and implication for oxidative stress and inflammation. Artif Organs. 2011;35(2):183–7. doi: .
    1. Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis. 2003;42(3):524–31. .
    1. Mitrogianni Z, Barbouti A, Galaris D, Siamopoulos KC. Tyrosine nitration in plasma proteins from patients undergoing hemodialysis. Am J Kidney Dis. 2004;44(2):286–92. .
    1. Schlesinger S, Sonntag SR, Lieb W, Maas R. Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: A systematic review and meta-analysis of prospective studies. PLoS One. 2016;11(11):e0165811 doi: ; PubMed Central PMCID: PMC5094762.
    1. Barreto FC, Barreto DV, Canziani MEF. Uremia retention molecules and clinical outcomes. Contrib Nephrol. 2017;191:18–31. doi: .
    1. Eloot S, Torremans A, De Smet R, Marescau B, De Wachter D, De Deyn PP, et al. Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int. 2005;67(4):1566–75. doi: .
    1. Sitar ME, Kayacelebi AA, Beckmann B, Kielstein JT, Tsikas D. Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids. 2015;47(9):1983–93. doi: .
    1. Raikou VD, Tentolouris N, Kyriaki D, Evaggelatou A, Tzanatou H. beta2-Microglobulin, pulse pressure and metabolic alterations in hemodialysis patients. Nephron Clin Pract. 2011;117(3):c237–45. doi: .
    1. Mercadal L, Franck JE, Metzger M, Urena Torres P, de Cornelissen F, Edet S, et al. Hemodiafiltration versus hemodialysis and survival in patients with ESRD: The french renal epidemiology and information network (REIN) registry. Am J Kidney Dis. 2016;68(2):247–55. doi: .
    1. Shroff R SC, Azukaitis K, Stefanidis CJ, Canpolat N, Krid S, Litwin MP. Haemodiafiltration (HDF) improves the cardiovascular risk profile compared to conventional haemodialysis (HD) in children-The HDF, Heart and Height (3H) Trial. J Am Soc Nephrol. 2017;28:83.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe